United Therapeutics Europe

Iron and zinc combined (internal code H.22.05.03.11.C2) is a fixed-dose combination therapeutic developed by United Therapeutics Europe Ltd for the treatment of anemia. The program combines two micronutrient components—iron and zinc—both classified within the alimentary tract and metabolism therapeutic class. The combination approach addresses anemia through nutritional supplementation, leveraging the synergistic roles of iron in oxygen transport and zinc in hematopoiesis and immune function.

The program has reached approved status as of the latest milestone dated 20 April 2018. Zinc, the primary active component disclosed in regulatory records, has achieved approval in both Australia (PBS code 7558T) and the European Union under the brand name Wilzin, with European Marketing Authorization Holder designation assigned to Recordati Rare Diseases and EMA authorization dated 16 December 2024 (EMEA/H/C/000535). The clinical development pathway is supported by trial NCT00470158, though detailed trial results and specific efficacy endpoints remain not yet disclosed in available intelligence.

United Therapeutics Europe Ltd's strategy appears focused on leveraging established micronutrient therapies for anemia management. The program's completion status and multi-jurisdictional approvals indicate successful regulatory navigation, though peak sales projections and commercial positioning details have not been disclosed. The combination formulation represents a potential differentiation strategy within the anemia treatment landscape, competing against both specialized rare disease therapeutics and conventional iron supplementation approaches.

Anemia remains a significant global health burden affecting over 1.6 billion people worldwide, with iron deficiency anemia representing the most common form. Zinc deficiency frequently co-occurs with iron deficiency, particularly in populations with malnutrition, chronic disease, or malabsorption disorders. A combined iron-zinc formulation addresses a recognized clinical gap by targeting both micronutrient deficiencies simultaneously, potentially improving therapeutic efficacy and patient compliance through simplified dosing.

The market relevance of this combination is substantial in both developed and developing healthcare systems. In developed markets, anemia management typically involves iron supplementation alone; however, zinc co-supplementation may enhance hematopoietic recovery and immune function in specific patient populations. In resource-limited settings, combined micronutrient formulations are increasingly recognized as cost-effective interventions for anemia prevention and treatment, particularly in pregnant women, children, and populations with chronic inflammatory conditions.

Competitive positioning reflects the program's differentiation within the anemia therapeutic space. While the competitor list includes rare disease therapeutics (ELAPRASE, REPLAGAL, VIMIZIM, MEPSEVII, BRINEURA) targeting specific genetic anemias and metabolic disorders, the iron-zinc combination occupies a distinct nutritional supplementation niche. The European approval through Recordati Rare Diseases suggests potential positioning within rare or refractory anemia indications, though the full clinical indication scope remains not yet disclosed. Commercial significance is underscored by multi-jurisdictional regulatory approvals and the established safety profile of both iron and zinc as individual agents, reducing regulatory risk and enabling rapid market penetration in approved territories.

Drug Class and Modality: Fixed-dose combination micronutrient supplement; classified as 'other' modality within pharmaceutical taxonomy.

Active Components:

• Iron: Essential trace element for hemoglobin synthesis and oxygen transport; mechanism of action in anemia correction well-established
• Zinc: Cofactor for multiple enzymes involved in hematopoiesis, immune function, and protein synthesis; therapeutic class A16 (Alimentary tract and metabolism)

Regulatory Designations:

• Zinc component approved in Australia (PBS code 7558T) and European Union (brand name Wilzin, EMEA/H/C/000535, Marketing Authorization Holder: Recordati Rare Diseases, authorization date 16 December 2024)
• Route of administration, specific formulation strength, and iron component regulatory status not yet disclosed

Related Therapies: Iron monotherapy (standard of care for iron deficiency anemia); zinc monotherapy (used in Wilson's disease, aceruloplasminemia, and zinc deficiency states); other micronutrient combinations (vitamin B12, folate co-supplementation in specific anemias).

Patent and Intellectual Property Status: Not yet disclosed.

European Union: Zinc component approved via centralized procedure; Marketing Authorization Holder: Recordati Rare Diseases; EMA Product Number: EMEA/H/C/000535; Authorization Date: 16 December 2024; Brand name: Wilzin.

Australia: Approved; PBS code 7558T; listed on Australian Register of Therapeutic Goods (TGA ARTG).

United States (FDA): Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Additional Regulatory Notes:

• Iron component regulatory status in EU and Australia not yet disclosed separately from zinc component
• Specific formulation approvals, indication scope, and any conditional or accelerated approval pathways not yet disclosed
• Post-marketing surveillance or risk management plan details not yet disclosed

Strategic Implications: United Therapeutics Europe Ltd's development of a fixed-dose iron-zinc combination reflects a strategic pivot toward nutritional therapeutics within the anemia market. The program's completion and multi-jurisdictional approvals indicate successful regulatory execution, though the absence of disclosed peak sales projections and commercial strategy details suggests either early-stage market development or niche positioning within rare anemia indications. The Recordati Rare Diseases partnership for European distribution implies positioning within rare disease channels rather than mass-market primary care.

Competitive Implications: The competitor list dominated by rare disease and metabolic disorder therapeutics indicates minimal direct competition in the nutritional supplementation segment. This positioning advantage is offset by the established market presence of generic iron and zinc monotherapies, which represent lower-cost alternatives. The combination's competitive differentiation depends on demonstrated clinical superiority in specific anemia subtypes—data not yet disclosed in available intelligence.

Future Catalysts and Expected Milestones:

• Publication of NCT00470158 trial results in peer-reviewed literature (not yet disclosed)
• Potential label expansion to additional anemia indications or patient populations
• Regulatory submissions in additional jurisdictions (FDA, PMDA, NMPA status unknown)
• Commercial uptake data and market penetration metrics in approved territories
• Potential partnerships or licensing agreements with additional distributors in non-European markets

Development Risks: The absence of disclosed mechanism of action details and trial results creates uncertainty regarding clinical differentiation. Regulatory approval does not guarantee commercial success in markets with established generic iron supplementation. Patent protection status unknown, creating potential generic competition risk.